Sarhyal Amit, Chate Sameeran, Tubaki Basavaraj R, Thakur Rajat
Department of Kaumarbhritya, Shri Satya Sai Murlidhar Ayurvedic College & Hospital, G.T. Road, Duneke Moga, Distt. Moga, Punjab, India.
Department of Psychiatry, J N Medical College. A Constituent Unit of KLE Academy of Higher Education & Research, Belagavi, Karnataka, India.
J Ayurveda Integr Med. 2024 Nov-Dec;15(6):101022. doi: 10.1016/j.jaim.2024.101022. Epub 2024 Dec 3.
Role of Ayurveda medications in the management of Major depressive disorder (MDD) is explored.
To evaluate the effect of Brahmi vati and Aswagandarista in the management of MDD.
Study was a Randomized, Controlled, parallel group comparative clinical trial. Fifty patients meeting the MDD (DSM V) diagnostic criteria from teaching hospital were recruited in the study. They were divided in two 2 groups. Control group were administered with Escitalopram 10 mg twice a day. Ayurveda group were intervened with tablet Brahmi vati 500 mg thrice a day and Liquid Aswagandarista 10 ml thrice a day. Interventions were for 60 days. Assessments were done on every 15th day. Assessments criteria included Hamilton Depression Rating scale (HDRS), Hamilton Anxiety Rating scale (HARS), UKU Side effect scale (UKU), Brief Psychotic Rating Scale (BPRS), WHO quality of life -BREF (WHOQOL-BREF), Pittsburgh Sleep Quality Index (PSQI) and Clinical Global Impression scales (CGI) were assessed at all the time points. Blood parameters like Haemoglobin, Serum creatinine and Liver function tests were evaluated at pre and post study.
Between group comparison showed significant improvements in WHOQOL-Bref (p < 0.001), UKU (p = 0.04) favouring Ayurveda group and PSQI (p = 0.02) improvements in control group. Improvements in other parameters were comparable. Within group assessment showed significant (p < 0.001) improvement in HDRS, HARS, BPRS, CGI-S, CGI-GI in both the groups. Liver function tests and serum creatines were within normative limits.
Ayurveda medications produced significant improvements comparable to escitalopram with additional advantages in quality of life and side effects profile.
探讨阿育吠陀药物在重度抑郁症（MDD）管理中的作用。
评估婆罗米丸和印度人参口服液对MDD的治疗效果。
本研究为随机、对照、平行组比较临床试验。从教学医院招募了50名符合MDD（DSM-V）诊断标准的患者。他们被分为两组。对照组每天两次服用10毫克艾司西酞普兰。阿育吠陀组每天三次服用500毫克婆罗米丸和每天三次服用10毫升印度人参口服液。干预为期60天。每15天进行一次评估。评估标准包括汉密尔顿抑郁量表（HDRS）、汉密尔顿焦虑量表（HARS）、UKU副作用量表（UKU）、简明精神病评定量表（BPRS）、世界卫生组织生活质量简表（WHOQOL-BREF）、匹兹堡睡眠质量指数（PSQI）和临床总体印象量表（CGI），在所有时间点进行评估。在研究前后评估血红蛋白、血清肌酐和肝功能测试等血液参数。
组间比较显示，阿育吠陀组在WHOQOL-Bref（p<0.001）、UKU（p=0.04）方面有显著改善，对照组在PSQI（p=0.02）方面有改善。其他参数的改善相当。组内评估显示，两组的HDRS、HARS、BPRS、CGI-S、CGI-GI均有显著（p<0.001）改善。肝功能测试和血清肌酐在正常范围内。
阿育吠陀药物产生了与艾司西酞普兰相当的显著改善，在生活质量和副作用方面具有额外优势。
